Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

Table 1 Baseline characteristics of ICI-treated patients

	533 cases
Age (years)	67 (18–93)
Male/female	373/160
ECOG performance status, 0/1/≥2	313/173/47
Number of dosing cycles, median	10 (1–103)
Observation period, median (days)	384 (21–1715)
History of prior immunotherapy	20
Comorbidity
Hypertension	152
Diabetes	89
Liver disease	39
Thyroid disorders	37
Tumor type
Lung cancer	209
Head-and-neck cancer	106
Malignant melanoma	50
Urothelial cancer	60
Gastric cancer	36
Esophageal cancer	27
Malignant mesothelioma	26
Others	19
Immune checkpoint therapy
Anti-PD-1 antibody	452
Nivolumab/pembrolizumab	328/124
Anti-PD-L1 antibody	44
Atezolizumab/durvalumab	32/12
Anti-CTLA-4 antibody (ipilimumab)	19
Combination of anti-PD-1 and CTLA-4 antibodies	18
Nivolumab and ipilimumab	18

ICI immune checkpoint inhibitor, PD-1 programmed death 1, PD-L1 programmed death-ligand 1, CTLA-4 cytotoxic T-lymphocyte antigen 4

ISSN: 1471-2407